A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/56 (2006.01)
Patent
CA 2276783
HIV-related weight loss, HIV-related cachexia and HIV-related wasting syndrome can be treated by administering therapeutic amounts of the steroid .DELTA.5- androstene-3.beta.-ol-7,17 dione and metabolizable precursors thereof, such as .DELTA.5-androstene-3.beta.-acetoxy-7,17 dione, which are readily metabolized in vivo to .DELTA.5-androstene-3.beta.-ol-7,17 dione. Such treatment can be prophylactic, modulatory, ameliorative or curative in nature.
On peut traiter la perte de poids liée au VIH, la cachexie liée au VIH et le syndrome de dépérissement lié au VIH en administrant des doses thérapeutiques du stéroïde .DELTA.5-androstène-3.beta.-ol-7,17 dione et de ses précurseurs métabolisables tels que le .DELTA.5-androstène-3.beta.-acétoxy-7,17 dione, lesquels sont rapidement métabolisés in vivo en .DELTA.5-androstène-3.beta.-ol-7,17 dione. Ce traitement peut être d'ordre prophylactique, modulateur, amélioratif ou curatif.
Lardy Henry A.
Pauza C. David
Humanetics Corporation
Ridout & Maybee Llp
LandOfFree
Use of .delta.5 androstenes in the treatment of hiv wasting... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of .delta.5 androstenes in the treatment of hiv wasting..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of .delta.5 androstenes in the treatment of hiv wasting... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1875774